 | Up a level |
2022
Subbiah, Vivek, Wolf, Jurgen, Konda, Bhavana, Kang, Hyunseok, Spira, Alexander, Weiss, Jared, Takeda, Masayuki, Ohe, Yuichiro, Khan, Saad, Ohashi, Kadoaki, Soldatenkova, Victoria, Szymczak, Sylwia, Sullivan, Loretta, Wright, Jennifer and Drilon, Alexander (2022). Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol., 23 (10). S. 1261 - 1274. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488
2021
Besse, Benjamin, Drilon, Alexander E., Solomon, Benjamin J., Subbiah, Vivek, Tan, Daniel Shao-Weng, Park, Keunchil, De Braud, Filippo G., Alonso, Guzman, Wolf, Juergen, Soldatenkova, Victoria, Lin, Aimee K., French, Pearl Plernjit, Goto, Koichi and Gautschi, Oliver (2021). Updated overall efficacy and safety of selpercatinib in patients (pts) with RET fusion plus non-small cell lung cancer (NSCLC). J. Clin. Oncol., 39 (15). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755
Drilon, Alexander E., Gautschi, Oliver, Besse, Benjamin, Subbiah, Vivek, Tan, Daniel Shao-Weng, Park, Keunchil, De Braud, Filippo G., Alonso, Guzman, Wolf, Juergen, Soldatenkova, Victoria, French, Pearl Plernjit, Lin, Aimee K., Goto, Koichi and Solomon, Benjamin J. (2021). Response to selpercatinib versus prior systemic therapy in patients (pts) with RET fusion plus non-small-cell lung cancer (NSCLC). J. Clin. Oncol., 39 (15). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755